Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke

Journal of Cerebral Blood Flow and Metabolism

Volumn 30, Issue 6, 2010, Pages 1137-1146

  Zhu, Haihao ^a   Fan, Xiang ^a   Yu, Zhanyang ^a   Liu, Jianxiang ^a   Murata, Yoshihiro ^a   Lu, Jie ^a   Zhao, Song ^a   Hajjar, Katherine A ^b   Lo, Eng H ^a   Wang, Xiaoying ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Annexin A2; Cerebral ischemia; Combination therapy; Thrombolysis; TPA

Indexed keywords

D DIMER; GELATINASE B; LIPOCORTIN 2; PLASMIN; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; ENZYME ACTIVATION; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; FOCAL EMBOLIC STROKE; LOW DRUG DOSE; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; RAT; TREATMENT OUTCOME;

ANIMALS; ANNEXIN A2; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FIBRINOLYSIN; HUMANS; INTRACRANIAL EMBOLISM; MALE; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 77953229376     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1038/jcbfm.2009.279     Document Type: Article

References (45)

1. Adams HP, Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF (2007) Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 115:e478-534
2. Aoki T, Sumii T, Mori T, Wang X, Lo EH (2002) Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 33:2711-2717
3. Armstead WM, Cines DB, Higazi AA (2005) Plasminogen activators contribute to impairment of hypercapnic and hypotensive cerebrovasodilation after cerebral hypoxia/ischemia in the newborn pig. Stroke 36:2265-2269
4. Armstead WM, Ganguly K, Kiessling JW, Chen XH, Smith DH, Higazi AA, Cines DB, Bdeir K, Zaitsev S, Muzy-kantov VR (2009) Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation. J Cereb Blood Flow Metab 29:1463-1474
5. Armstead WM, Nassar T, Akkawi S, Smith DH, Chen XH, Cines DB, Higazi AA (2006) Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat Neurosci 9:1150-1155
6. Asahi M, Asahi K, Wang X, Lo EH (2000) Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J Cereb Blood Flow Metab 20:452-457
7. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H (1986) Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17:472-476
8. Benchenane K, Berezowski V, Fernandez-Monreal M, Brillault J, Valable S, Dehouck MP, Cecchelli R, Vivien D, Touzani O, Ali C (2005) Oxygen glucose deprivation switches the transport of tPA across the blood-brain barrier from an LRP-dependent to an increased LRP-independent process. Stroke 36:1065-1070
9. Cheng T, Petraglia AL, Li Z, Thiyagarajan M, Zhong Z, Wu Z, Liu D, Maggirwar SB, Deane R, Fernandez JA, LaRue B, Griffin JH, Chopp M, Zlokovic BV (2006) Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med 12:1278-1285
10. Davalos A (2005) Thrombolysis in acute ischemic stroke: successes, failures, and new hopes. Cerebrovasc Dis 20(Suppl 2):135-139
11. Gravanis I, Tsirka SE (2008) Tissue-type plasminogen activator as a therapeutic target in stroke. Expert Opin Ther Targets 12:159-170
12. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D (2008) Thrombolysis with alteplase 3 to 4.5h after acute ischemic stroke. N Engl J Med 359:1317-1329
13. Hajjar KA, Acharya SS (2000) Annexin II and regulation of cell surface fibrinolysis. Ann NY Acad Sci 902:265-271
14. Hajjar KA, Krishnan S (1999) Annexin II: a mediator of the plasmin/plasminogen activator system. Trends Cardio-vasc Med 9:128-138
15. Hajjar KA, Menell JS (1997) Annexin II: a novel mediator of cell surface plasmin generation. Ann NY Acad Sci 811:337-349
16. Henninger N, Bouley J, Bratane BT, Bastan B, Shea M, Fisher M (2009) Laser Doppler flowmetry predicts occlusion but not tPA-mediated reperfusion success after rat embolic stroke. Exp Neurol 215:290-297
17. Ishii H, Yoshida M, Hiraoka M, Hajjar KA, Tanaka A, Yasukochi Y, Numano F (2001) Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery. Circ Res 89:1240-1245
18. Kaur J, Zhao Z, Klein GM, Lo EH, Buchan AM (2004) The neurotoxicity of tissue plasminogen activator? J Cereb Blood Flow Metab 24:945-963
19. Kim J, Hajjar KA (2002) Annexin II: a plasminogen-plasminogen activator co-receptor. Front Biosci 7:d341-8
20. Korninger C, Collen D (1981) Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost 46:561-565
21. Lapchak PA, Araujo DM, Song D, Wei J, Purdy R, Zivin JA (2002) Effects of the spin trap agent disodium-[tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit Large clot embolic stroke model: combination studies with tissue plasminogen activator. Stroke 33:1665-1670 (Pubitemid 34619976)
22. Lee SR, Wang X, Tsuji K, Lo EH (2004) Extracellular proteolytic pathophysiology in the neurovascular unit after stroke. Neurol Res 26:854-861
23. Lo EH, Broderick JP, Moskowitz MA (2004) tPA and proteolysis in the neurovascular unit. Stroke 35:354-356
24. Marder VJ, Landskroner K, Novokhatny V, Zimmerman TP, Kong M, Kanouse JJ, Jesmok G (2001) Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost 86:739-745
25. Marks MP, Olivot JM, Kemp S, Lansberg MG, Bammer R, Wechsler LR, Albers GW, Thijs V (2008) Patients with acute stroke treated with intravenous tPA 3 to 6 h after stroke onset: correlations between MR angiography findings and perfusion-and diffusion-weighted imaging in the DEFUSE study. Radiology 249:614-623
26. Morris DC, Zhang L, Zhang ZG, Lu M, Berens KL, Brown PM, Chopp M (2001) Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke. Stroke 32:2635-2640
27. Nassar T, Akkawi S, Shina A, Haj-Yehia A, Bdeir K, Tarshis M, Heyman SN, Higazi AA (2004) In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood 103:897-902
28. Pfefferkorn T, Rosenberg GA (2003) Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 34:2025-2030
29. Sakharov DV, Rijken DC (1995) Superficial accumulation of plasminogen during plasma clot lysis. Circulation 92:1883-1890
30. Sheehan JJ, Tsirka SE (2005) Fibrin-modifying serine proteases thrombin, tPA, and plasmin in ischemic stroke: a review. Glia 50:340-350
31. Strbian D, Karjalainen-Lindsberg ML, Kovanen PT, Tatli-sumak T, Lindsberg PJ (2007) Mast cell stabilization reduces hemorrhage formation and mortality after administration of thrombolytics in experimental is-chemic stroke. Circulation 116:411-418
32. Tanaka Y, Ishii H, Hiraoka M, Miyasaka N, Kuroiwa T, Hajjar KA, Nagaoka T, Duong TQ, Ohno K, Yoshida M (2007) Efficacy of recombinant annexin 2 for fibrinolytic therapy in a rat embolic stroke model: A magnetic resonance imaging study. Brain Res 1165:135-143
33. Thomalla G, Schwark C, Sobesky J, Bluhmki E, Fiebach JB, Fiehler J, Zaro Weber O, Kucinski T, Juettler E, Ringleb PA, Zeumer H, Weiller C, Hacke W, Schellinger PD, Rother J (2006) Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6h in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke 37:852-858
34. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasmi-nogen activator for acute ischemic stroke. N Engl J Med 333:1581-1587
35. Wang X, Asahi M, Lo EH (1999) Tissue type plasminogen activator amplifies hemoglobin-induced neurotoxicity in rat neuronal cultures. Neurosci Lett 274:79-82
36. Wang X, Lee SR, Arai K, Lee SR, Tsuji K, Rebeck GW, Lo EH (2003) Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 9:1313-1317
37. Wang X, Lo EH (2003) Triggers and mediators of hemor-rhagic transformation in cerebral ischemia. Mol Neuro-biol 28:229-244
38. Wang X, Rosell A, Lo EH (2008) Targeting extracellular matrix proteolysis for hemorrhagic complications of tPA stroke therapy. CNS Neurol Disord Drug Targets 7:235-242
39. Wang X, Tsuji K, Lee SR, Ning M, Furie KL, Buchan AM, Lo EH (2004) Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 35:2726-2730
40. Yepes M, Roussel BD, Ali C, Vivien D (2009) Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci 32:48-55
41. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA (2003) Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 112:1533-1540
42. Zhang C, An J, Strickland DK, Yepes M (2009) The low-density lipoprotein receptor-related protein 1 mediates tissue-type plasminogen activator-induced micro-glial activation in the ischemic brain. Am J Pathol 174: 586-594
43. Zhang L, Zhang ZG, Liu X, Hozeska A, Stagliano N, Riordan W, Lu M, Chopp M (2006) Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator. Thromb Haemost 95:166-173
44. Zhang L, Zhang ZG, Zhang R, Morris D, Lu M, Coller BS, Chopp M (2003) Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke. Circulation 107:2837-2843
45. Zhao BQ, Wang S, Kim HY, Storrie H, Rosen BR, Mooney DJ, Wang X, Lo EH (2006) Role of matrix metalloprotei-nases in delayed cortical responses after stroke. Nat Med 12:441-445